Autologous transplantation of CD133 selected hematopoietic progenitor cells in a pediatric patient with relapsed leukemia.
A pediatric patient with very early meningeal relapse of his CD34(+) CD133(-) pre-B-ALL was transplanted with 2.5 x 10(6)/kg CD133 selected autologous progenitor cells. Enrichment of CD133(+) cells resulted in a purity of 92.3 +/- 3.5% CD133(+). Hematopoietic engraftment with >1.0 x 10(9)/l neutrophils and >50 x 10(9)/l platelets was reached within 13 and 24 days, respectively. At a follow-up of 11(1/2) months after autologous transplantation, the patient is in complete remission. To our knowledge, the successful transplantation with a CD133 selected graft is the first one to be reported worldwide. CD133 selected cells may serve as an alternative in the case of CD34(+) malignancy.
Koehl
U
U
University Hospital Frankfurt, Department of Pediatric Hematology and Oncology, Frankfurt, Germany.
Zimmermann
S
S
Esser
R
R
Sörensen
J
J
Grüttner
H P
HP
Duchscherer
M
M
Seifried
E
E
Klingebiel
T
T
Schwabe
D
D
D000071916:AC133 Antigen; D000208:Acute Disease; D015703:Antigens, CD; D002648:Child; D006023:Glycoproteins; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D008297:Male; D010455:Peptides; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D012074:Remission Induction; D016879:Salvage Therapy; D014182:Transplantation, Autologous / Q000379:methods
D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides